Depression-Fighting Molecule Study Gets US Patent
Bursa Uludağ University Faculty of Medicine Medical Pharmacology Department academic Prof. Dr. Sinan Çavun and his team's study which asserts the use of "Glycyl-glutaminin" (Gly-Gln) molecule in the treatment of depression has been secured by US patent, after the acquisiton of European patent.
Bursa Uludağ University Faculty of Medicine Medical Pharmacology Department academics Prof. Dr. Sinan Çavun and Assoc. Dr. Mustafa Sertaç Yılmaz had proved the efficacy of Gly-Gln, which is synthesized in the body during the destruction of "B-endorphin" known as "Happiness hormone", in the treatment of depression.
Prof. Çavun said that with the acquisition of the European and United States patents, all rights of the invention will protected for 20 years.
In addition to taking the patents, they have also taken a considerable distance in the ongoing studies on experimental animals. Prof. Dr. Çavun These experiments have shown that the molecule that is given to people in the right way is very effective in the treatment of depression. We have now found that the Gly-Gln molecule shows a slightly better effect in the treatment of depression than the existing drugs in comparative experiments. The fact that Gly-Gln is also superior to other existing drugs, especially because of its side-effects, is a distinct advantage because it is a molecule already present in our bodies "
"MAY BE THE NATIONAL MEDICINE"
Prof. Dr. Çavun noted that this data is very important for the future, but in the next steps the costs will gain importance. He said: "These toxicological tests and clinical phases wil require support from the state or investor pharmaceutical companies. We hope that there will be positive developments in terms of "national medicine". "If we, Turkish scientists, can contribute to the treatment of such a major disease as depression, it will be the greatest pride for us."